Zacks Investment Research cut shares of vTv Therapeutics Inc. (NASDAQ:VTVT) from a hold rating to a sell rating in a research note published on Wednesday.
According to Zacks, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. “
A number of other equities analysts have also weighed in on VTVT. Canaccord Genuity restated a buy rating and issued a $15.00 target price on shares of vTv Therapeutics in a research note on Friday, August 19th. HC Wainwright assumed coverage on vTv Therapeutics in a research note on Monday, September 26th. They issued a buy rating and a $13.00 target price on the stock.
vTv Therapeutics (NASDAQ:VTVT) traded down 0.29% during trading on Wednesday, hitting $6.96. The company had a trading volume of 1,309 shares. The stock’s market capitalization is $67.44 million. vTv Therapeutics has a 1-year low of $4.84 and a 1-year high of $8.22. The company’s 50 day moving average price is $6.50 and its 200-day moving average price is $5.92.
vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings data on Tuesday, August 16th. The company reported ($0.47) earnings per share (EPS) for the quarter. On average, analysts expect that vTv Therapeutics will post ($1.61) EPS for the current year.
A number of institutional investors have recently made changes to their positions in the company. BlackRock Investment Management LLC raised its position in shares of vTv Therapeutics by 25.3% in the second quarter. BlackRock Investment Management LLC now owns 27,758 shares of the company’s stock worth $161,000 after buying an additional 5,596 shares in the last quarter. Geode Capital Management LLC raised its position in shares of vTv Therapeutics by 2.4% in the first quarter. Geode Capital Management LLC now owns 34,884 shares of the company’s stock worth $180,000 after buying an additional 822 shares in the last quarter. Kennedy Capital Management Inc. acquired a new position in shares of vTv Therapeutics during the first quarter worth $282,000. State Street Corp raised its position in shares of vTv Therapeutics by 10.9% in the first quarter. State Street Corp now owns 61,239 shares of the company’s stock worth $316,000 after buying an additional 6,000 shares in the last quarter. Finally, BlackRock Institutional Trust Company N.A. raised its position in shares of vTv Therapeutics by 23.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 96,439 shares of the company’s stock worth $559,000 after buying an additional 18,112 shares in the last quarter. Institutional investors and hedge funds own 12.84% of the company’s stock.
About vTv Therapeutics
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.